Opinion ID: 219633
Heading Depth: 2
Heading Rank: 1

Heading: Starmark's '373 Patent

Text: The application for the '373 Patent was filed on December 18, 2003, claiming priority to a provisional application filed on December 18, 2002. The '373 Patent discloses creatine salts comprising two molecules of creatine and one molecule of dicarboxylic acid. Id. col. 3, ll. 55-59. These embodiments purport to provide hydrosoluble creatine salts. Id. Claims 1-6 cover creatine salts, whereas claims 7-13 cover methods of making these creatine salts. Independent claim 1 recites:
wherein A represents an anion of a dicarboxylic acid. Dependent claim 3 recites: 3. The creatine salt of claim 1, wherein A is an anion of malic acid. Independent claim 7, representative of the method claims, recites: 7. A process comprising reacting a molar excess of creatine monohydrate and a dicarboxylic acid or a tricarboxylic acid with heat to form a creatine salt having the formula: The '373 Patent issued on September 19, 2006, to SAN Corporation (SAN) listing SAN's CEO, Matthias Boldt (Boldt), as the sole inventor. In October 2006, Boldt formed Starmark, where he serves as CEO, president, and sole shareholder. All right, title, and interest in the '373 Patent was then assigned to Starmark.